Irina Antonijevic Biography and Net Worth

Dr. Antonijevic is a seasoned drug developer with over 20 years of experience in drug development, with a focus on neurologic and psychiatric disorders. She has worked in large and small pharma and biotech organizations and multiple different patient communities. She has brought novel drugs with different mechanisms of actions and different modalities from discovery through preclinical development into clinical trials. Prior to her industry career, Dr. Antonijevic completed her residency training in psychiatry, psychotherapy as well as neurology at the renowned Clinic of the Max Planck Institute for Psychiatry, Germany, where she also directed her own clinical research into the neurobiological underpinnings of neuropsychiatric disorders.

In 2001, Dr. Antonijevic embarked on an industry career, with the objective to develop novel, more targeted, better-understood and safe medicines for high unmet needs in the field of neuropsychiatry. Starting as Core Clinician for Central Nervous System Disorders at Schering AG, now Bayer, she took roles with increasing responsibilities, from Lundbeck Research USA, to CHDI, a privately funded, not-for-profit biomedical research organization devoted exclusively to Huntington’s disease, a life shortening, inherited neurodegenerative disease, to Sanofi Genzyme, where she was head of Early Development Multiple Sclerosis, Neurology and Ophthalmology. Subsequently, she took on a role as Chief Medical Officer (CMO) at vasopharm GmbH, a Germany based private company developing a novel drug for severe traumatic brain injury, followed by a role as VP of Translational Medicine and Development at Wave Life Science, before taking on the role of CMO and then subsequently also Head of R&D at Triplet Therapeutics, where she has led development of a novel therapeutic approach for repeat expansion disorders such as Huntington’s disease, spinocerebellar ataxias and Myotonic Dystrophy. In July 2022, Dr. Antonijevic took on the role of CMO at EveryONE Medicines, a start-up biotech company dedicated to creating a path for approval and commercialization of individualized precision therapeutics for rare genetic disorders.

Dr. Antonijevic obtained her PhD in basic neurophysiological research from the University of Edinburgh, UK. She is a board-certified psychiatrist and received her venia legendi from the Berlin University, Germany. She has been a member of the supervisory board of 4SC AG since 2012, and of Paion AG from 2017 through early 2022.